No connection

Search Results

SILO vs TNON

SILO
Silo Pharma, Inc.
BEARISH
Price
$0.52
Market Cap
$8.4M
Sector
Healthcare
AI Confidence
95%
TNON
Tenon Medical, Inc.
BEARISH
Price
$0.80
Market Cap
$9.0M
Sector
Healthcare
AI Confidence
90%

Valuation

P/E Ratio
SILO
--
TNON
--
Forward P/E
SILO
-0.74
TNON
-1.28
P/B Ratio
SILO
1.09
TNON
4.41
P/S Ratio
SILO
116.19
TNON
2.29
EV/EBITDA
SILO
-0.1
TNON
-0.72

Profitability

Gross Margin
SILO
38.57%
TNON
59.79%
Operating Margin
SILO
-4363.27%
TNON
-193.52%
Profit Margin
SILO
0.0%
TNON
0.0%
ROE
SILO
-74.56%
TNON
-228.06%
ROA
SILO
-35.63%
TNON
-72.88%

Growth

Revenue Growth
SILO
0.0%
TNON
92.3%
Earnings Growth
SILO
--
TNON
--

Financial Health

Debt/Equity
SILO
--
TNON
0.03
Current Ratio
SILO
11.36
TNON
2.11
Quick Ratio
SILO
10.55
TNON
1.7

Dividends

Dividend Yield
SILO
--
TNON
--
Payout Ratio
SILO
0.0%
TNON
0.0%

AI Verdict

SILO BEARISH

SILO exhibits critical financial distress, highlighted by a Piotroski F-Score of 0/9, indicating a total lack of fundamental improvement across all measured categories. The company is currently pre-revenue or stagnant (0% YoY growth) with an unsustainable operating margin of -4363.27%. While a high current ratio of 11.36 suggests a temporary cash runway, the long-term trajectory is severely negative with a 5-year price decline of 96%. The recent 1-month price spike appears to be speculative volatility rather than a fundamental turnaround.

Strengths
Strong short-term liquidity (Current Ratio: 11.36)
Price/Book ratio near 1.09 suggests the stock is trading close to its accounting value
Recent short-term price momentum (+60.9% in 1 month)
Risks
Extreme fundamental weakness (Piotroski F-Score 0/9)
Zero revenue growth (YoY and Q/Q)
Massive operating losses (-4363.27% operating margin)
TNON BEARISH

TNON exhibits critical financial fragility with a Piotroski F-Score of 1/9, signaling severe weakness in profitability and operational efficiency. While the company shows impressive top-line momentum with 92.3% YoY revenue growth and maintains a low debt profile, these are overshadowed by a catastrophic -193.52% operating margin and a -228.06% ROE. The long-term price performance is devastating, with a near 100% loss over 5 years, suggesting a failed historical value proposition. Despite optimistic analyst price targets, the deterministic health metrics indicate a high risk of continued equity erosion.

Strengths
Strong YoY revenue growth of 92.30%
High gross margin of 59.79% indicating product value
Very low leverage with a Debt/Equity ratio of 0.03
Risks
Critical financial health as evidenced by Piotroski F-Score of 1/9
Severe operational losses with an operating margin of -193.52%
Extreme equity erosion indicated by ROE of -228.06%

Compare Another Pair

SILO vs TNON: Head-to-Head Comparison

This page compares Silo Pharma, Inc. (SILO) and Tenon Medical, Inc. (TNON) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile